Similar to the findings of the current study demonstrating invariant TRP/CAA ratio after treatment with anti-TNF-α, it was shown adalimumab, which is also a TNF-α antagonist, exerts its immune-suppressant effect without influencing IDO activity and TRP levels in patients with rheumatoid arthritis [51]. This evidence concerns the gene TNF and rheumatoid arthritis.